Pharmacological, pharmacokinetic and clinical profile of meloxicam

被引：12
作者：
Degner, F
Turck, D
Pairet, M
机构：
[1] Boehringer Ingelheim KG, D-55216 Ingelheim, Germany
[2] Dr Karl Thomae GmbH, D-7950 Biberach, Germany
来源：
DRUGS OF TODAY | 1997年 / 33卷 / 10期
关键词：
D O I：
10.1358/dot.1997.33.10.451138
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：739 / 758
页数：20
相关论文
共 77 条
[41]  
MOHR W, 1997, J RHEUMATOL, V56, P21
[42]  
MULLER FO, 1995, EUR J CLIN PHARMACOL, V48, P247
[43]   An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure [J].
Muller, FO ;
Middle, MV ;
Schall, R ;
Terblanche, J ;
Hundt, HKL ;
Groenewoud, G .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (04) :393-398
[44]  
NARJES H, 1996, BR J CLIN PHARM, V36, P135
[45]  
NARJES H, 1996, SCAND J RHEUMAT S106, V25, P61
[46]   Meloxicam [J].
Noble, S ;
Balfour, JA .
DRUGS, 1996, 51 (03) :424-430
[47]   Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1 [J].
Ogino, K ;
Hatanaka, K ;
Kawamura, M ;
Katori, M ;
Harada, Y .
PHARMACOLOGY, 1997, 55 (01) :44-53
[48]   Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: Possible physiological and therapeutic implications [J].
Pairet, M ;
Engelhardt, G .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1996, 10 (01) :1-15
[49]  
PAIRET M, 1995, INFLAMM RES S3, V44
[50]  
PAIRET M, 1997, IN PRESS SELECTIVE C
12345678